According to recent epidemiologic data, reductions in prostate-specific antigen (PSA) screenings are likely the underlying cause of observed increases in cases of metastatic prostate cancer in the United States
“To reduce the incidence of metastatic prostate cancer in the United States, we support policies that promote shared decision making to optimize PSA screening, such as the updated United States Preventive Services Task Force [USPSTF] guidelines,” study author Vidit Sharma, MD, a chief resident in the Department of Urology at Mayo Clinic, said during a poster presentation of the data during the 2021 Genitourinary Cancers Symposium.
PSA screening was found to reduce metastases and mortality in patients with prostate cancer, according to results from the randomized ERSPC trial. However, screening has also been known to result in significant harms from overdiagnosis and…
